How Europe approves medicines for rare diseases. The importance of having data.
Putting a new drug on the market requires on average 5 years from the authorization perspective. So how can this process be accelerated and how can patients contribute to this?
Patients are producing data and data is the fuel of power for decisions. Good quality information can be collected with the help of strong patient organizations, but it also has to be FAIR: Findable, Accessible, Interoperable and Reusable. And the Dravet Syndrome European Federation is going FAIR!
With this discussion we kicked off our webinar series for 2022. The session around the approval process for drugs by the European authorities was facilitated by our Chief Scientific Officer, Luis Miguel Aras, having as guest speaker Julian Isla, Scientific Advisor of DSEF and also member of the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA).
Thank you to all our participants – representing quite a number of countries: Spain, Italy, Germany, France, Croatia, Norway, Romania, Slovenia, Serbia, Ireland and Iraq.
Looking forward to having you at our next events!
Horizons for Dravet Syndrome 2018 • 5th edition
“40 Year Dravet Syndrome” Diagnosis and management of Dravet Syndrome – From unmet medical needs to best practices
Vienna, Austria
Horizons for Dravet Syndrome 2018 • 4th edition
Dravet Syndrome and other sodium channel related encephalopathies
Verona, Italy
